Bright Path Labs chosen as a collaborator in a first-ever National Science Foundation Engines Award
Bright Path is proud to have been chosen to collaborate with the The Puerto Rico Science, Technology, & Research Trust in a $1M NSF Innovation Engines Development Award
Bright Path Laboratories Awarded EQUIP-A- Pharma Agreement to Revolutionize Pharmaceutical Manufacturing
Agreement Awarded by DARPA in partnership with the Administration for Strategic Preparedness and Response’s (ASPR) Center of Industrial Base Management and Supply Chain (IBMSC) Kannapolis, NC / College Station, Tx August 28, 2024 – Bright Path Laboratories, Inc., a...
Bright Path Labs Develops Potential Life Saving Drug for Children with Rare Disease
On Rare Disease Day 2024, Bright Path Laboratories shared an amazing step in our commitment to rare diseases. Bright Path successfully completed the development of Amlexanox as a potential treatment for WOREE Syndrome, a devastating rare disease that affects children...
Bright Path Labs is Solving Drug Shortages with Domestic Development and Manufacturing of Cancer Medicines
KANNAPOLIS, N.C., Dec. 13, 2023 /PRNewswire/ -- Bright Path Laboratories, a US-based advanced drug development and manufacturing company is proud to announce their contribution to solving drug shortages for the domestic development and manufacturing of two critical...
Supply Chain Crisis in America
Our nation's over-dependence on foreign pharmaceutical production has left America vulnerable. The Covid-19 pandemic revealed that the U.S. is dangerously exposed to supply chain disruptions. Our limited domestic manufacturing capabilities of lifesaving medicines is a...
Capstone Health Alliance and Bright Path Laboratories Enter Into Agreement To Address Drug Shortages
Bright Path Labs chosen as a collaborator in a first-ever National Science Foundation Engines Award
GC3 Membership and Innovators Roundtable Invitation
Bright Path Labs is proud to announce its admittance to the Green Chemistry and Commerce Council (GC3)! We are eager to learn from and collaborate with leaders in sustainable and green technologies across different sectors. Our technology and approach are deeply...
Life Sciences Supply Chain Disruptions Likely to Persist through 2022
Supply chain disruption will be with biopharmaceutical companies for the foreseeable future, according to the recent CFO survey, Supply Chain Resilience, by BDO. A separate report by Catalent, Allogeneic and Autologous Cell Therapies Report 2022, agrees, saying,...
Tony Quinones on the Latest on Covid Vaccines – Bloomberg
Tony Quinones, CEO of Bright Path Laboratories, discusses the latest on the omicron variant and Covid vaccines with Bryan Curtis and Paul Allen on Bloomberg Daybreak Asia.
Bright Path CEO explains the importance of producing pharmaceutical drugs in the U.S.
Bright Path CEO Tony Quinone joins Yahoo Finance to discuss how the Build Back Better Plan will promote locally produced pharmaceutical drugs.